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“Every disadvantage has its advantage” (elk nadeel heb z’n voor-
deel), says Johan Cruijff, the Netherlands’ greatest soccer player,
in one of his most famous quotes. Every time completeness and
accessibility of follow-up data in screening evaluation are in
play, I am extremely conscious of this quote. It was under
Napoleon Bonaparte, actually, that a population registry started
in the Netherlands, in the same process by which he conquered
large parts of Europe while leaving behind a path of destruction
and death. On the positive side of this legacy, current registry
systems that uniformly cover 100% of the actual population al-
low us to approach each individual and link follow-up data to
them. Among other things, they help ensure high-quality can-
cer screening.
In cancer screening, equity and an optimal balance between
harms and benefits can only be achieved with the most com-
plete reach or coverage of the population possible, as well as in-
formed choice for participation and adequate follow-up of
positive screenings and outcomes. Cancer registries and popu-
lation registries, therefore, play a fundamental role in all of
these steps. Such registries will be even more important when
future screening programs tackle specific risk groups, such as
lung cancer screening, more so than age groups alone. This is
also true for when prevention programs become more precision
strategies, tailoring tests by specific intervals to earlier individ-
ual results. Notwithstanding the many difficulties in achieving
these goals (1), such registries have been crucial in European
screening programs.
Policymakers and analysts in the United States have often
struggled with the lack of such rich uniformly available data
sources, while Europeans have sometimes questioned evalua-
tions in more decentralized systems. Shapiro and others were
one of the first to try to assemble and compare metrics across
countries (2). In vain, it seemed, given the limited amount of
comparative papers (3). But citizens and policymakers need
benchmarking, as colorectal cancer (CRC) screening is being
gradually implemented, different tests are being used through-
out the world, and new testing technologies are emerging, such
as breast tomosynthesis and human papilloma virus testing.
Citizens may ask: Do I get maximum benefits versus limited
harm? Or should I refrain from too much testing? Policymakers
may ask: Is this program ideal? Should we introduce or make
the newest test available?
Providing a uniform centralized data source was exactly
what Barlow et al. (4) intend to do in this issue of the Journal.
The Population-based Research Optimising Screening through
Personalised Regimens (PROSPR) consortium, comprised of 10
research centers across the United States, reflects the diversity
of US health-care delivery models. They provide performance
metrics across different cancer types, using a noteworthy
framework. They assess the important downstream steps in the
screening process over the 2010–2014 period by analyzing
screening data from health information systems, cancer out-
come data from Surveillance, Epidemiology and End Results
and statewide cancer registries, as well as tumor and pathology
records.
Their findings of those “being tested up-to-date” were 63.5%
in breast screening for women aged 40–74 years and approxi-
mately 67% for those aged 50–74 years; 84.6% in cervical screen-
ing for women aged 21–64 years and approximately 87% for
those aged 30–64 years; and 77.5% for colorectal cancer screen-
ing for individuals aged 50–75 years, with 85.9% for those aged
65–75 years. These percentages include those receiving testing
regardless of indication and those not in need of screening
based on testing in prior years. These results can be seen as im-
portant achievements in the US health-care system. Although
they do compensate for the difficulty of taking appropriate
screening interval recommendations into account, they do not
provide answers to the debate about the most appropriate inter-
val to consider here. Some of these percentages could perhaps
still include overtesting, according to other standards (5,6).
Referral rates varied between 4.1% and 5.4% in CRC and 2.4%
and 6.2% in cervical cancer (CC) but were highest in breast can-
cer with 8.2% and 14.6%. Barlow and co-authors (4) do not report
predictive values of positive tests. Many women and men will
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ask, what is the probability of me having cancer after getting a
referral? The correct answer is that we cannot yet tell at the in-
dividual level, but for groups as a whole, it ranges from 0.39% in
CC to 3.2% in CRC and 5.3% in breast cancer. Admittedly, some
preneoplastic lesions in CC and CRC should be counted here
too. Such metrics are not easy to interpret given the differences
in health-care systems, but at first glance, the referral rates do
seem important reductions compared to earlier single institu-
tion reports.
Whether these referrals and especially detection rates are
appropriate benchmark values is even more difficult to grasp
and evaluate. A very rough measurement to apply could be the
cancers per 1000 screens, or the detection rate, compared to the
“underlying incidence rate,” as a gauge of the earlier diagnosis
by screening. If we were to take, with caution but possibly incor-
rectly, cancers per 1000 persons in the population off the table,
we would get estimates between 1.8 and 2.4. These could per-
haps contribute interesting additional raw figures, also when
comparing age categories.
The advantage of European linkable one-to-one registries,
after consent, is perhaps still seen in Barlow’s definition of can-
cer diagnosis (4), including all incidents of cancers detected
within 1 year of a screening test among those who had at least 1
year of follow-up. For the more rapidly growing cancers, such as
breast cancer and lung cancer, these estimates seem to include
possible interval cancers, that is, diagnosed cancers in the 1
year after a negative screen result. These are a crucial measure-
ment of performance and test sensitivity and need specific link-
ages (7).
With few reports of metrics for cancer screening that follow
a target population from risk assessment through cancer diag-
nosis, this PROSPR initiative is very important and timely, given
the future of new screening tests and cancer screening pro-
grams. Barlow et al. (4) start their paper with a preamble warn-
ing that population-based cancer screening can be achieved
only if there is high participation by screen-eligible individuals
coupled with appropriate and timely follow-up of abnormal
findings. I think it would be appropriate to end by stressing
three additional metrics for PROSPR’s future: treatment parame-
ters, interval cancers, and informed choice. I am certain the fu-
ture of cancer screening evaluation in the United States and
PROSPR is bright, as Barlow and colleagues’ paper is indicative
of metrics to come. Or should I say, “every cloud has a silver
lining.”
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